Search by Categories
- Insights
- Rare Disease
- Oncology
- Cell and Gene Therapy
- Medical Devices
- Consulting
- News & Analysis
- Therapeutic Areas
Our expertise in the industry
Immunomedics discontinues its trial early – hopes for accelerated approval of Sacituzumab govitecan for mTNBCImmunomedics- a New Jersey-based pharmaceutical company has announced to freeze its...
More than a dozen companies have shifted their focus towards the Hormone Receptor positive (HR+), human epidermal growth factor receptor 2 (HER2) negative breast cancer therapeutic area. Some of ...
Hormone Receptor (HR)-positive/ Human Epidermal Receptor 2 (HER2)-negative Breast Cancer is the most prevalent form of breast cancer. This type accounts for a higher percentage among all breast ca...
Breast cancer is not a single disease leading to abnormal cell division in breast tissues. In the United States, it is estimated that more than 40,000 women will die from breast cancer in 2017. Ac...
Gordon and Betty Moore Foundation gives USD 85 Million to stop delayed, erroneous diagnosticsThe Gordon and Betty Moore Foundation is putting up money for improving diagnostics. The Foundation fo...
Human Immunodeficiency Virus or HIV is a species of Lentivirus (genus of retrovirus) th...
Progress is driven by innovation. When it comes to developing novel medications and the...
The HIV-1 treatment market for naïve and experienced patients is evolving consistently....
The Pharmaceuticals segment of the Healthcare Industry has a significant market across ...
Von Willebrand disease is a type of blood disorder that causes the blood to clot improp...
Hear from our subject-matter experts and in-house KOL’s on Pharma and Healthcare market trends.
